Xem mẫu

480 INSULIN RESISTANCE, HYPERTENSION AND ENDOTHELIAL DYSFUNCTION 26. Vallance, P., Collier, J. and Moncada, S. (1989) Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 2, 997–1000. 27. Yki-Jarvinen, H. and Utriainen, T. (1998) Insulin-induced vasodilatation: Physiology or pharmacology? Diabetologia 41, 369–379. 28. Ueda, S., Petrie, J. R., Cleland, S. J., Elliott, H. L. and Connell, J. M. C. (1998) The vasodilating effect of insulin is dependent on local glucose uptake: A double blind, placebo-controlled study. J Clin Endocrinol Metab 83, 2126–2131. 29. Cleland, S. J., Petrie, J. R., Ueda, S., Elliott, H. L. and Connell, J. M. C. (1999) Insulin-mediated vasodilationand glucose uptake are functionally linked in humans. Hypertension 33, 554–558. 30. Ueda, S., Petrie, J. R., Cleland, S. J., Elliott, H. L. and Connell, J. M. C. (1998) Insulin vasodilatation and the ‘arginine paradox’. Lancet 351, 959–960. 31. Zeng, G. and Quon, M. J. (1996) Insulin-stimulated production of nitric oxide is inhibited by Wortmannin: Direct measurement in vascular endothelial cells. J Clin Invest 98, 894–898. 32. Aljada, A. and Dandona, P. (2000) Effect of insulin on human aortic endothelial nitric oxide synthase. Metab Clin Exp 49, 147–150. 33. Kuboki, K., Jiang, Z.-Y., Takahara, N., Ha, S.-W., Igarashi, M., Yamauchi, T., Feener, E. P., Herbert, T. P., Rhodes, C. J. and King, G. L. (2000) Regulation of constitutive nitric oxide synthase gene expression in endothelial cells and in vivo. A specific vascular action of insulin. Circulation 101, 676–681. 34. Sobrevia, L., Nadal, A., Yudilevich, D. L. and Mann, G. E. (1996) Activation of L-arginine transport (system y+) and nitric oxide synthase by elevated glucose and insulin in human endothelial cells. J Physiol 490, 775–781. 35. Petrie, J. R., Ueda, S., Webb, D. J., Elliott, H. L. and Connell, J. M. C. (1996) Endothelial nitric oxide production and insulin sensitivity: A physiological link with implications for pathogenesis of cardiovascular disease. Circulation 93, 1331–1333. 36. Cleland, S. J., Petrie, J. R., Small, M., Elliott, H. L. and Connell, J. M. C. (2000) Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension 35(1), 507–511. 37. Abe, H., Yamada, N., Kuwaki, T., Shimada, M., Osuga, J., Shionoiri, F., Yahagi, N., Kadowaki, T., Tamemoto, H., Ishibashi, S., Yazaki, Y. and Makuuchi, M. (1998) Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 101, 1784–1788. 38. Jiang, Z. Y., Lin, Y.-W., Clemont, A., Feener, E. P., Hein, K. D., Igarashi, M., Yamauchi, T., White, M. F. and King, G. L. (1999) Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 104, 447–457. 39. Pinkney, J. H., Stehouwer, C. D. A., Coppack, S. W. and Yudkin, J. S. (1997) Endothe-lial dysfunction: Cause of the insulin resistance syndrome. Diabetes 46, S9–S13. 40. Baron, A. D. (1994) Hemodynamic actions of insulin. Am J Physiol – Endocrinol Metab 267, E187–E202. 41. Utriainen, T., Nuutila, P., Takala, T., Vicini, P., Ruotsalainen, Ronnemaa, T., Tolva-nen, T., Raitakari, M., Haaparanta, M., Kirvela, O., Cobelli, C. and Yki-Jarvinen, H. (1997) Intact insulin stimulation of skeletal muscle blood flow, its heterogeneity and redistribution, but not of glucose uptake in non-insulin-dependent diabetes mellitus. J Clin Invest 100, 777–785. 42. Natali, A., Bonadonna, R., Santoro, D., Galvan, A. Q., Baldi, S., Frascerra, S., Palombo, C., Ghione, S. and Ferrannini, E. (1994) Insulin resistance and vasodilation in essential hypertension. Studies with adenosine. J Clin Invest 94, 1570–1576. REFERENCES 481 43. Nuutila, P., Raitakari, M., Laine, H., Kirvela, O., Takala, T., Utriainen, T., Makimat-tila, S., Pitkanen, O.-P., Ruotsalainen, U., Iida, H., Knuuti, J. and Yki-Jarvinen, H. (1996) Role of blood flow in regulating insulin-stimulated glucose uptake in humans: Stud-ies using bradykinin, [15O]water, and [18F]fluoro-deoxy-glucose and positron emission tomography. J Clin Invest 97, 1741–1747. 44. Shankar, R. R., Wu, Y., Shen, H.-Q., Zhu, J.-S. and Baron, A. D. (2000) Mice with disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 49, 684–687. 45. Hayashi, T., Wojtaszewski, J. F. P. and Goodyear, L. J. (1997) Exercise regulation of glucose transport in skeletal muscle. Am J Physiol – Endocrinol Metab 273, E1039–E1051. 46. Young, M. E., Radda, G. K. and Leighton, B. (1997) Nitric oxide stimulates glucose transport and metabolism in rat skeletal muscle in vitro. Biochem J 322, 223–228. 47. Collison, M., Glazier, A. M., Graham, D., Morton, J. J., Dominiczak, M. H., Ait-man, T. J., Connell, J. M., Gould, G. W. and Dominiczak, A. F. (2000) Cd36 and molec-ular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes 49, 2222–2226. 48. Williams, S. B., Cusco, J. A., Roddy, M.-A., Johnstone, M. T. and Creager, M. A. (1996) Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27, 567–574. 49. Steinberg, H. O., Chaker, H., Leaming, R., Johnson, A., Brechtel, and Baron, A. D. (1996) Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97, 2601–2610. 50. Hogikyan, R. V., Galecki, A. T., Pitt, B., Halter, J. B., Greene, D. A. and Supiano, M. A. (1998) Specific impairment of endothelium-dependent vasodilation in subjects with type 2 diabetes independent of obesity. J Clin Endocrinol Metab 83, 1946–1952. 51. Nitenberg, A., Paycha, F., Ledoux, S., Sachs, R., Attali, J.-R. and Valensi, P. (1998) Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation 97, 736–743. 52. Makimattila, B.,Liu, M.-L.,Vakkilainen, J.,Schlenzka, A.,Lahdenpera, S.,Syvanne, M., Mantysaari, M., Summanen, P., Bergholm, R., Taskinen, M.-R. and Yki, Jarvinen, H. (1999) Impaired endothelium-dependent vasodilation in type 2 diabetes: Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care 22, 973–981. 53. Tooke, J. E. and Goh, K. L. (1999) Vascular function in Type 2 diabetes mellitus and pre-diabetes: The case for intrinsic endotheliopathy. Diabet Med 16, 710–715. 54. Caballero, A. E., Arora, S., Saouaf, R., Lim, S. C., Smakowski, P., Park, J. Y., King, G. L. L., Horton, E. S. and Veves, A. (1999) Microvascular and macrovas-cular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48, 1856– 1862. 55. Valverde, A. M., Teruel, T., Navarro, P., Benito, M. and Lorenzo, M. (1998) Tumor necrosis factor-alpha causes insulin receptor substrate-2-mediated insulin resistance and inhibits insulin-induced adipogenesis in fetal brown adipocytes. Endocrinology 139, 1229–1238. 56. Feinstein, R., Kanety, H., Papa, M. Z., Lunenfeld, B. and Karasik, A. (1993) Tumor necrosis factor-alpha supresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268, 26055–26058. 57. Halse, R., Pearson, S. L., McCormack, J. G., Yeaman, S. J. and Taylor, R. (2001) Effects of tumor necrosis factor-α on insulin action in cultured human muscle cells. Diabetes 50, 1102–1109. 482 INSULIN RESISTANCE, HYPERTENSION AND ENDOTHELIAL DYSFUNCTION 58. Wang, P., Ba, Z. E. and Chaudry, I. H. (1994) Administration of tumour necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 266, H2535–H2541. 59. Ruan, H., Hacohen, N., Golub, T. R., Van Parijs, L. and Lodish, H. F. (2002) Tumor necrosis factor-α suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-κB activation by TNF-α is obligatory. Diabetes 51, 1319–1336. 60. Dandona, P., Aljada, A., Mohanty, P., Ghanim, H., Hamouda, W., Assian, E. and Ahmad, S. (2001) Insulin inhibits intranuclear nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86, 3257–3265. 61. Peraldi, P., Xu, M. and Spiegelman, B. M. (1997) Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest 100, 1863–1869. 62. Hundal, R. S., Petersen, K. F., Mayerson, A. B., Randhawa, P. S., Inzucchi, S., Shoel-son, S. E. and Shulman, G. I. (2002) Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109, 1321–1326. 63. Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z. W., Karin, M. and Shoelson, S. E. (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293, 1673–1677. 64. Ventre, J., Doebber, T., Wu, M., MacNaul, K., Stevens, K., Pasparakis, M., Kollias, G. and Moller, D. E. (1997) Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. Diabetes 46, 1526–1531. 65. Ofei, F., Hurel, S., Newkirk, J., Sopwith, M. and Taylor, R. (1996) Effects of an engineered human anti-TNF-a antibody (CPD571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45, 881–885. 66. Stears, A. J. and Byrne, C. D. (2001) Adipocyte metabolism and the metabolic syndrome. Diabetes Obes Metab 3, 129–142. 67. Saltiel, A. R. and Kahn, R. C. (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799–806. 68. Shulman, G. I. (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106, 171–176. 69. Bermudez, E. A., Rifai, N., Buring, J., Manson, J. E. and Ridker, P. M. (2002) Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscleros Thrombos Vasc Biol 22, 1668–1673. 70. Han, T. S., Sattar, N., Williams, K., Gonzalez-Villalpando, C., Lean, M. E. J. and Haffner, S. M. (2002) Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25, 2016–2021. 71. Festa, A., D’Agostino, R., Tracy, R. P. and Haffner, S. M. (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51, 1131–1137. 72. Bastard, J.-P., Maachi, J., Van Nhieu, J. T., Jardel, C., Brucker, E., Grimaldi, A., Robert, J.-J., Capeau, J. and Hainque, B. (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87, 2084–2089. 73. Mantzoros, C. S. (1999) The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 130, 671–680. 74. Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S. and Goldstein, J. L. (1999) Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401, 73–76. REFERENCES 483 75. Steppan, C. M., Brown, E. J., Wright, C. M., Bhat, S., Banerjee, R. R., Dai, C. Y., Enders, G. H., Silberg, D. G., Wen, X., Wu, G. D. and Lazar, M. A. (2001) A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 98, 502–506. 76. Nagaev, I. and Smith, U. (2001) Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 285, 561–564. 77. Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., Ezaki, O., Akanuma, Y., Gavrilova, O., Vinson, C., Reitman, M. L., Kagechika, H., Shudo, K., Yoda, M., Nakano, Y., Tobe, K., Nagai, R., Kimura, S., Tomita, M., Froguel, P. and Kadowaki, T. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med 7, 941–946. 78. Lindsay, R. S., Funahashi, T., Hanson, R. L., Matsuzawa, Y., Tanaka, S., Tataranni, P. A., Knowler, W. C. and Krakoff, J. (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360, 57–8. 79. Adamczak, M., Wiecek, A., Funahashi, T., Chudek, J., Kokot, F. and Matsuzawa, Y. (2003) Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 16, 72–75. 80. Kumada, M., Kihara, S., Sumitsuji, S., Kawamoto, T., Matsumoto, S., Ouchi, N., Arita, Y., Okamoto, Y., Shimomura, I., Hiraoka, H., Nakamura, T., Funahashi, T. and Matsuzawa, Y. (2003) Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscleros Thrombos Vascr Biol 23, 85–9. 81. Steinberg, H. O., Tarshoby, M., Monestel, R., Hook, G., Cronin, J., Johnson, A., Bayazeed, B. and Baron, A. D. (1997) Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100, 1230–1239. 82. deKreutzenberg, S. V., Crepaldi, C., Marchetto, S., Calo, L. and Tiengo, A. (2000) Plasma free fatty acids and endothelium-dependent vasodilation: Effect of chain-length and cyclooxygenase inhibition. J Clin Endocrinol Metab 85, 793–798. 83. Davda, R. K., Stepniakowski, K. T., Lu, G., Ullian, M. E., Goodfriend, T. L. and Egan, B. M. (1995) Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism. Hypertension 26, 764–770. 84. Moller, D. E. (2001) New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414, 821–827. ... - tailieumienphi.vn
nguon tai.lieu . vn